04:52 PM EDT, 09/30/2024 (MT Newswires) -- ChitogenX ( CHNXF ) , a clinical-stage regenerative medicine company, Monday said its fiscal second-quarter loss narrowed.

The company reported a loss of $300,000 in the quarter ended July 31, compared to a loss of $400,000 in the year-prior period.

Revenue was not disclosed.

"We continued to maintain our R&D and administrative expenses to a strict minimum as demonstrated by their significant decreases on a quarterly and year-to-date comparison basis," said Chief Financial Officer Luc Mainville. "With a 79% reduction in R&D and administrative expense so far this year compared to the prior year, we are committed to keep advancing our grant-supported research and strategic initiatives to help secure funding from commercial partners or other non-dilutive avenues."